Institute of Molecular and Cell Biology
A*STAR

SEMINAR ANNOUNCEMENT

We would like to invite you to attend this seminar hosted by Prof. Hong Wanjin:

Date: 19 September 2019, Thursday
Time: 11:00AM – 12:00NN
Venue: Level 3, IMCB Seminar Room 3-46, Proteos, Biopolis

Speaker: Prof. Hartmut Juhl, Founder & CEO, Indivumed GmbH, Hamburg, Germany
Title: IndivuType: A truly multiomics cancer database for the cure of cancer

Abstract
In today's era of precision oncology therapeutics, there is an ever-growing need for developing unique patient signatures. The delivery of truly personalized treatments for cancer have been stymied by limitations heretofore insurmountable: a single-layer omics approach to research; sample acquisition quality and biobank variability; and limited clinical information – all of which impede clinicians' and pharmaceutical and biotech companies'
efforts to develop and deliver effective cancer treatments.

IndivuType is the result of Indivumed's more than fifteen years' experience in collecting and curating high-quality, highly controlled and protected, cancer biospecimens from surgical settings through partnerships with leading healthcare institutions around the world. IndivuType contains vast amounts of genomics, transcriptomics, proteomics, phosphoproteomics and immuno-phenotype imaging information, as well as deep and rich clinical and outcome data. IndivuType is enhanced with machine learning tools and artificial intelligence.

IndivuType is a discovery and knowledge platform developed for clinicians and the pharmaceutical industry to create and accelerate new insights into cancer biology, leading to better and more affordable drug development for precision medicine and the personalized treatment of cancer. IndivuType's powerful database can forge a path to accelerate clinical trials, enable robust protocol design, and generate insights for precision oncology treatment and improved patient outcomes.

Biography
Dr. Hartmut Juhl is an entrepreneur, surgical oncologist, and world-renowned researcher dedicated to the science of tissue quality and precision medicine in cancer. 1987 to 1998 he was trained and worked as a surgical oncologist at University Clinic of Hamburg and Kiel. Focussing on translational cancer research, he became Associate Professor ate Lombardi Cancer Center, Georgetown University. In 2001, he founded and became CEO of Indivumed GmbH in Hamburg, Germany. Hartmut Juhl holds an adjunct professorship at the Medical Faculty of Hamburg University, and the Lombardi Cancer Center of Georgetown University, and has served as an

advisor to several institutions including the U.S. National Cancer Institute. He received several awards including the “Hamburg Foundation Prize” in the category of “Founders of new Businesses” in 2003, the German Foundation Prize in the category of “New Visionary” in 2005 and the AACR Team Award 2017 as member of “The International Liquid Biopsy Initiative Team”.

ALL ARE WELCOME *(No registration required)*

We appreciate if you could disseminate this email to your staff.

For upcoming seminars in IMCB, please visit our website at https://www.a-star.edu.sg/imcb

Thank you.

Note: This message may contain confidential information. If this Email/Fax has been sent to you by mistake, please notify the sender and delete it immediately. Thank you.